I am a
Home I AM A Search Login

Papers of the Week

2021 Jun 25

Clin Res Hepatol Gastroenterol

Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.


Baumann U, Sturm E, Lacaille F, Gonzalès E, Arnell H, Fischler B, Jørgensen M H, Thompson RJ, Mattsson JP, Ekelund M, Lindström E, Gillberg P-G, Torfgård K, Soni PN
Clin Res Hepatol Gastroenterol. 2021 Jun 25:101751.
PMID: 34182185.


Ileal bile acid transporter inhibition is a novel therapeutic concept for cholestatic pruritus and cholestatic liver disease progression. Odevixibat, a potent, selective, reversible ileal bile acid transporter inhibitor, decreases enteric bile acid reuptake with minimal systemic exposure. Oral odevixibat safety, tolerability, and efficacy in pediatric patients with cholestatic liver disease and pruritus were evaluated.